Ambrx has a number of highly differentiated product candidates at various stages of development in its pipeline, with a focus on discovering and developing best-in-class biopharmaceutical product opportunities. We also have a number of undisclosed partnerships with assets at various stages of development.
Expanded Access Policy
patients, such as ARX788.
At this time, Ambrx does not offer an expanded access program and is not accepting expanded
access requests for investigational products, such as ARX788. Ambrx’ current focus and priority
is to complete the product development program for its investigational product(s), such as
ARX788, to obtain the required safety and efficacy data needed for regulatory approval. We
believe that focusing our resources on our clinical trial programs is the best path forward to bring
our investigational product(s) to patients as quickly and safely as possible. Patients can gain access to our investigational product(s), such as ARX788, by participating in our clinical trials. If you would like to learn more about Ambrx’ clinical trials, please view www.clinicaltrials.gov.
If you have additional questions about Ambrx’ expanded access policy, please email us at
As we continue to develop investigational product(s), we will review our expanded access policy
for investigational product(s) and may make updates to this policy. For more information about
expanded access in the U.S., please visit the FDA website at https://www.fda.gov/newsevents/public-health-focus/expanded-access.